Loading...
•
Jun 30, 2022
Ionis Q2 2022 Earnings Report
Ionis reported positive eplontersen ATTRv-PN data and is on track to file NDA in H2:22, with tofersen NDA under priority review and PDUFA set for January 25, 2023.
Key Takeaways
Ionis Pharmaceuticals reported strong second quarter results with total revenues of $134 million and a net loss of $105 million on a GAAP basis. The company highlighted advancements in its pipeline, including positive Phase 3 data for eplontersen and the acceptance of the NDA for tofersen. With $2.0 billion in cash and short-term investments, Ionis is on track to achieve its 2022 financial guidance.
Reported positive Phase 3 data from the NEURO-TTRansform study of eplontersen in patients with hereditary ATTR polyneuropathy and are on track to file an NDA in the second half of this year.
FDA accepted the NDA for tofersen and granted priority review, enabling it to potentially be the first disease modifying treatment approved for a genetic form of ALS.
The pelacarsen Lp(a) HORIZON and olezarsen BALANCE Phase 3 studies recently completed enrollment.
Reported positive data from six mid-stage programs, positioning the company to grow its Phase 3 pipeline to at least eight medicines across 10 indications.
Revenue by Segment
Forward Guidance
Ionis is on track to achieve its 2022 financial guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...